drugset / Trial / NCT02979392
Phase I Study of TENPA in Advanced Solid Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to investigate the safety and to determine maximum tolerated dose and recommended phase 2 dose of TENPA (Targeting-Enhancing Nanoparticles of Paclitaxel) in patients with advanced solid tumor.
Timeline
- Start
- 2016-05-02
- Primary completion
- 2019-07-04
- Completion
- 2019-07-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paclitaxel | Small molecule | 75 mg/m2 | Intravenous |